CompletedPhase 3

Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-2

United States613 participantsStarted 2015-11

Plain-language summary

This is a multicenter, randomized, double-blind study of the efficacy and safety of iclaprim compared to vancomycin for the treatment of skin and skin structure infections.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. written informed consent;
✓. ≥18 years of age;
✓. a bacterial infection of the skin with a lesion size area of at least 75 cm2;
✓. a major cutaneous abscess, cellulitis/erysipelas, and/or wound infections;
✓. the presence of purulent or seropurulent drainage or at least three signs and symptoms of infection (discharge, erythema, swelling, warmth, or pain).

Exclusion criteria

✕. severely impaired arterial blood supply such that amputation of the infected anatomical site is likely;
✕. infected diabetic foot ulcers;
✕. infected decubitus ulcers;
✕. necrotizing fasciitis or gangrene;
✕. uncomplicated skin or skin structure infection;
✕. infections associated with a prosthetic device;
✕. suspected or confirmed osteomyelitis;
✕. conditions requiring systemic anti-microbial treatment, prophylaxis, or suppression therapy.

What they're measuring

Percent of Participants With ≥20% Reduction in Lesion Size at 48 to 72 Hours Compared to Baseline

Timeframe: Baseline and 48 to 72 hours after first dose of study drug

Trial details

NCT IDNCT02607618

SponsorMotif Bio

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2017-08-08

Results submitted2018-06-14

View on ClinicalTrials.gov More Skin Structures and Soft Tissue Infections trials